



For Immediate Release

New York, January 13, 2016

## **Indxx LLC Launches Indxx Global Generics & New Pharma Index, Licensed to Van Eck for Exchange Traded Fund**

Indxx LLC is pleased to announce the launch of the Indxx Global Generics & New Pharma Index. The index has been licensed to noted New York-based ETF issuer Van Eck Associates Corporation (“Van Eck”) for their exclusive use as the underlying benchmark for the Market Vectors Generic Drugs ETF, which began trading today on the NASDAQ (symbol: GNRX).

Indxx’s research division believes the global generic drug industry is primed for strong growth due to a number of short and long-term trends occurring worldwide, including aging populations in the developed world seeking to reduce their drug costs, newly emerging economies with billions of potential consumers of generic drugs, and numerous popular brand-name drugs that will soon be losing patent protection. Indxx will be preparing research pieces to introduce and explore these trends on a regular basis.

“We at Indxx are excited to have developed this index for Van Eck by using the cutting-edge capabilities of our research and analytics divisions to identify a unique trend and properly target it via an index-based approach” said Rahul Sen Sharma, Partner at Indxx. “We look at it as another example of how we seek to distinguish ourselves as a custom index provider that adds value throughout the index development process.”

“Van Eck is proud to be launching the first ETF to offer investors targeted exposure to the generic drugs space” said Edward Lopez, Marketing Director at Van Eck Global. “We believe that there are a number of exciting trends in the space that make it a compelling and unique investment opportunity. We also look forward to our newest index provider relationship with Indxx. Their research capabilities helped bring this idea to life with an index we believe effectively captures the global nature of investing in generic drug manufacturers.”

The index includes exchange-listed companies, on a global basis, that derive a significant proportion of their revenues (or that have the potential to derive a significant proportion of their revenues) from the generic drug industry, or that have a primary business focus on the generic drug industry.

The index was backtested to March 18, 2005 with an original value of 1,000. There are two versions of the index currently available, a total return (ticker: IGNRXT) and price return version (ticker: IGNRXP). As of December 31, 2015, the index included 83 securities of companies with a weighted average market capitalization of \$25.65 billion. These amounts are subject to change.

### **About Indxx**

Founded in 2005, Indxx seeks to redefine the global indexing space. With offices in New York, London and New Delhi, the firm focuses on Index Development, Index Calculation, Analytics & Research and combines these services in a holistic, customized approach that is unique to the industry and provides maximum benefits to our clients.



For more information about Indxx or the Indxx Global Generics & New Pharma Index, visit:  
<http://www.indxx.com/>

For further information about this press release, please contact:

Indxx Press & Media Relations  
Attention: Anika Bhardwaj  
Phone: +1-844-55-INDXX  
Email: [info@indxx.com](mailto:info@indxx.com)